Novartis signs manufacturing deal for Kymriah in China

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) has agreed to manufacture and supply Kymriah tisagenlecleucel in China for Novartis AG (NYSE:NVS; SIX:NOVN). The pharma said the deal will help it gain market access in China for the CAR T therapy. Cellular Biomedicine has three Chinese GMP facilities in Shanghai, Beijing and Wuxi.